SCHEDULE: Amneal Shareholder Pledges 3M Shares for $10M Loan

A trust controlled by Amneal Pharmaceuticals' significant shareholder, Dipan Patel, has pledged 3,050,000 Class A Common Stock shares as collateral for a $10 million loan from Enterprise Bank & Trust.

Summary

• AP-1 Trust, an entity controlled by Dipan Patel, a significant shareholder of Amneal Pharmaceuticals, Inc., entered into a Security Agreement with Enterprise Bank & Trust.
• This agreement secures a promissory note for a principal sum of $10,000,000.00.
• The collateral for the loan includes 3,050,000 shares of Amneal Pharmaceuticals (NYSE: AMRX) Class A Common Stock, held in account number AAA-7135 at Morgan Stanley Smith Barney LLC.
• Enterprise Bank & Trust holds a first priority security interest in the pledged collateral.
• The obligations under the loan documents are set to mature on November 5, 2026.
• Dipan Patel beneficially owns 23,828,992 shares of Amneal Pharmaceuticals Class A Common Stock, representing 7.6% of the class.
• The percentage of ownership is based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in Amneal's Quarterly Report on Form 10-Q filed on August 7, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a significant block of shares is pledged, introducing a potential overhang, the transaction itself is a shareholder-level financing event and does not directly reflect on the operational health or strategic direction of Amneal Pharmaceuticals. It provides liquidity to the shareholder but also carries risks of forced selling.

Positives

• A trust controlled by a significant shareholder successfully secured a $10 million loan, potentially providing liquidity for other investments or needs.

Negatives

• A substantial block of 3,050,000 Amneal Pharmaceuticals shares is pledged as collateral, creating a potential overhang if the loan defaults and the shares are foreclosed upon.
• The borrower (AP-1 Trust) has waived several rights and defenses, granting significant power to the lender (Enterprise Bank & Trust) in the event of default.
• The loan agreement includes acceleration clauses, allowing the lender to demand immediate repayment if there is a change of control or a 25% or more change in ownership of the borrower (if an entity), without prior consent.

Risks

• Risk of foreclosure on 3,050,000 Amneal Pharmaceuticals Class A Common Stock shares if the AP-1 Trust defaults on the $10 million promissory note.
• Potential negative market impact on Amneal Pharmaceuticals' share price if the lender forecloses on and sells a large block of shares.
• The borrower is prohibited from selling, leasing, or otherwise disposing of any collateral without the prior written consent of the lender.
• A change of control or a 25% or more change in ownership of the AP-1 Trust (if an entity) could trigger the acceleration of the loan, making all secured obligations immediately due and payable.

Future Outlook

The filing primarily details a past financing transaction and its terms for a significant shareholder. It does not provide forward-looking statements or guidance regarding Amneal Pharmaceuticals' operational or financial performance.

Industry Context

This filing pertains to a specific financing arrangement undertaken by a significant individual shareholder of Amneal Pharmaceuticals, rather than a direct operational or strategic update from the company itself. It does not directly reflect broader industry trends for the pharmaceutical sector, but rather a shareholder's personal liquidity or investment strategy.

Comparison to Industry Standards

• This filing details a specific shareholder's financing arrangement, not the operational or financial performance of Amneal Pharmaceuticals. Therefore, a direct comparison to industry-standard company performance benchmarks or specific comparable projects is not applicable.

Stakeholder Impact

• Shareholders of Amneal Pharmaceuticals: There is a potential for increased selling pressure on Amneal's stock if the pledged shares are foreclosed upon and subsequently sold by Enterprise Bank & Trust due to a loan default.
• Enterprise Bank & Trust (Lender): The bank gains a first priority security interest in a significant block of Amneal shares, providing substantial collateral for its $10 million loan.
• AP-1 Trust / Dipan Patel (Borrower): The trust obtains $10 million in financing but faces the risk of losing 3,050,000 Amneal shares if the loan obligations are not met.

Next Steps

• The borrower (AP-1 Trust) must promptly observe and perform all secured obligations under the loan documents until the maturity date of November 5, 2026.
• The borrower is required to furnish non-privileged written reports and information regarding obligors, account debtors, payment history, and agings for any third-party obligations included in the collateral upon the lender's demand.
• The lender (Enterprise Bank & Trust) is authorized to inspect the collateral, including the original books and records of the borrower, and may file financing statements to perfect its security interest.

Key Dates

Recommendation

The filing details a significant shareholder's financing arrangement, involving the pledge of a notable portion of their Amneal Pharmaceuticals stock as collateral for a loan. While this introduces a potential overhang on the stock due to the risk of future forced sales, it does not provide new information regarding Amneal Pharmaceuticals' operational performance, financial health, or strategic outlook. Therefore, a seasoned investor or institution would likely maintain their current position, focusing on the company's fundamentals rather than reacting solely to this shareholder-specific transaction.

Keywords

Amneal Pharmaceuticals, AMRX, Dipan Patel, Security Agreement, Promissory Note, Share Pledge, SEC Filing, Schedule 13D, Enterprise Bank & Trust, Collateral, Shareholder Financing